• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name: hematopoietic stem cells modified with a lentiviral vector containing the CD18 (Integrin Beta 2) gene
Date Designated: 11/09/2016
Orphan Designation: Treatment of leukocyte adhesion deficiency Type I
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Rocket Pharmaceuticals, Inc.
The Empire State Building
350 Fifth Avenue, Suite 7530
New York, New York 10118
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.